PolyAurum Announces New Chief Scientific Officer

November 13, 2017

PolyAurum announced today that Dr. Thais Sielecki, PhD will join the company as Vice President and Chief Scientific Officer.  Dr. Sieleck comes to PolyAurum after a distinguished career working for companies such as Cytokine, Bristol-Myers Squibb and Dupont Merck.  She has a successful track record and expertise in the areas of preclinical and early clinical science while maintaining an innovative and creative approach toward leadership. She has extensive experience in managing projects in drug delivery, oncology, inflammation, anti-infectives, and women’s health with multiple IND submittals as well as managing the scientific/business development/legal/regulatory teams with leadership in decision making on product portfolio balance, therapeutic area focus, and overall research/development strategy.


Dr. Sielecki earned her BS in Organic Chemistry and Psychology  from the University of Maryland, her PhD in Organic Chemistry from  Colorado State University and did post-doctoral studies in organic chemistry at Stanford University.  “Thais is the perfect person to head up our early development efforts and to help us stay focussed on filing an IND to start clinical studies. We are thrilled to have her on board”, said Deb Travers, PolyAurum’s President and CEO.


Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out / Change )

Twitter picture

You are commenting using your Twitter account. Log Out / Change )

Facebook photo

You are commenting using your Facebook account. Log Out / Change )

Google+ photo

You are commenting using your Google+ account. Log Out / Change )

Connecting to %s